›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:OncoScreen™ Focus CDx Tissue Kit
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Burning Rock BiotechType:
CE Marked
Related tests:
9ms
Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib (IASLC-WCLC 2023)
The EGFRexon20ins concordance between tumor tissue-based and plasma ctDNA testing is high. Antitumor activity of sunvozertinib was robust regardless of tumor tissue-based or plasma ctDNA tests. Both tests can be applied for identifying patients who potentially benefit from sunvozertinib treatment.
Clinical • EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR wild-type • KIT mutation • EGFR exon 20 mutation
|
OncoCompass™ Target • OncoScreen™ Focus CDx Tissue Kit
|
sunvozertinib (DZD9008)
1year
Clinical outcomes and molecular features of different histopathologic patterns in patients with stage IB non-squamous non-small-cell lung cancer (AACR 2023)
Our study confirms that S/MP pattern is a significantly worse prognostic factor for DFS in nsNSCLC and that there are significant differences in molecular features between these two different histopathologic patterns. qPCR-based assay could reliably identify patients with a worse prognosis in S/MP pattern, suggesting that such patients are most likely to benefit from personalized adjuvant therapy.
Clinical data • Clinical
|
EGFR mutation
|
DetermaRx™ • OncoScreen™ Focus CDx Tissue Kit
Share
